South Korea
· Delayed Price · Currency is KRW Celltrion Company Description
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea.
The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis.
The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis.
Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
| Country | South Korea |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,391 |
Contact Details
Address: 23 Academy-ro Incheon South Korea | |
| Phone | 82 3 2850 5000 |
| Website | celltrion.com |
Stock Details
| Ticker Symbol | 068270 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7068270008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jin-seok Seo | Co-Chief Executive Officer and Inside Co-Chairman of the Board |
| Woo-Sung Kee | Chief Executive Officer and Internal Director |
| Hyong-Gi Kim | Chief Executive Officer and Internal Director |
| Stephen Yeum | Founder |
| Min-Cheol Shin | Director of Finance |
| Ji-Hoon Choi | Director of Legal Affairs |